限制性平均生存时间分析评估台湾2型糖尿病患者SGLT2i对心肾结局一级和二级预防的异质性治疗效果
本研究为台湾全民健康保险研究数据库的比较效果研究,采用倾向性评分匹配分别评估心血管结局(21144对)和肾脏结局(19951对)的2型糖尿病患者,比较稳定使用SGLT2i与DPP4i的差异。随访至2018年12月31日,采用限制性平均生存时间(RMST)和Cox模型分析。结果显示,SGLT2i组2年RMST较DPP4i组延长:心衰住院4.99天(95%CI 3.56-6.42)、3P-MACE 4.12天(2.72-5.52)、4P-MACE 7.72天(5.83-9.61)、心肌梗死1.26天(0.47-2.04)、卒中2.70天(1.57-3.82)、心血管死亡0.69天(0.28-1.11)、全因死亡6.05天(4.89-7.20)、慢性肾病14.75天(12.99-16.52)。Cox模型风险比方向与RMST一致,阴性对照结局无关联,敏感性分析支持主分析结果。作者认为RMST分析可行,能将治疗效果转化为更直观的临床估计,并有助于量化异质性治疗效果。
要点
- 在21144对倾向性评分匹配的2型糖尿病患者中,SGLT2i较DPP4i的2年心衰住院RMST延长4.99天(95%CI 3.56-6.42)。
- 在19951对匹配患者中,SGLT2i较DPP4i的2年慢性肾病RMST延长14.75天(95%CI 12.99-16.52)。
- SGLT2i较DPP4i的2年全因死亡RMST延长6.05天(95%CI 4.89-7.20),心血管死亡延长0.69天(95%CI 0.28-1.11)。
- 已确诊心衰患者的心衰住院RMST差异最大,为30.80天(95%CI 5.08-56.51);视网膜病变患者的慢性肾病RMST差异最大,为40.43天(95%CI 31.74-49.13)。
- Cox模型风险比方向与RMST估计一致,阴性对照结局(牙科就诊)与治疗无关联,高维倾向性评分匹配和加权敏感性分析结果一致。
适用人群与场景
- 台湾2型糖尿病患者,2017年新开始稳定使用SGLT2i或DPP4i者。
- 心血管结局分析纳入21144对倾向性评分匹配的SGLT2i与DPP4i使用者。
- 肾脏结局分析纳入19951对倾向性评分匹配的SGLT2i与DPP4i使用者。
研究设计与关键结果
- 研究类型:比较效果研究,使用台湾全民健康保险研究数据库,采用倾向性评分匹配。
- 心血管结局分析:21144对匹配患者,SGLT2i组平均(SD)年龄58.3(10.7)岁,男性11990例(56.7%);DPP4i组平均(SD)年龄58.1(11.6)岁,男性12163例(57.5%)。
- 肾脏结局分析:19951对匹配患者,SGLT2i组平均(SD)年龄58.1(10.7)岁,男性11231例(56.2%);DPP4i组平均(SD)年龄57.9(11.5)岁,男性11340例(56.8%)。
- 2年RMST差异(SGLT2i vs DPP4i):心衰住院4.99天(95%CI 3.56-6.42),3P-MACE 4.12天(95%CI 2.72-5.52),4P-MACE 7.72天(95%CI 5.83-9.61),心肌梗死1.26天(95%CI 0.47-2.04),卒中2.70天(95%CI 1.57-3.82),心血管死亡0.69天(95%CI 0.28-1.11),全因死亡6.05天(95%CI 4.89-7.20),慢性肾病14.75天(95%CI 12.99-16.52)。
- Cox模型风险比方向与RMST估计一致;研究治疗与阴性对照结局(牙科就诊)无关联;高维倾向性评分匹配和倾向性评分加权敏感性分析结果一致。
- 亚组分析:已确诊心衰患者的心衰住院RMST差异最大,为30.80天(95%CI 5.08-56.51);视网膜病变患者的慢性肾病RMST差异最大,为40.43天(95%CI 31.74-49.13)。
证据类型、等级与局限
- 证据类型:比较效果研究(基于索赔数据库的倾向性评分匹配分析)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,RMST分析可行,可将治疗效果转化为更直观的临床估计,并有助于在常规临床环境中量化异质性治疗效果。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Increasing numbers of post hoc analyses have applied restricted mean survival time (RMST) analysis on the aggregated-level data from clinical trials to report treatment effects, but studies that use individual-level claims data are needed to determine the feasibility of RMST analysis for quantifying treatment effects among patients with type 2 diabetes in routine clinical settings.
OBJECTIVES: To apply RMST analysis for assessing sodium-glucose cotransporter-2 inhibitor (SGLT2i)-associated cardiovascular (CV) events and estimating heterogenous treatment effects (HTEs) on CV and kidney outcomes in routine clinical settings.
DESIGN, SETTING, AND PARTICIPANTS: This comparative effectiveness study of Taiwan's National Health Insurance Research Database examined 21 144 propensity score (PS)-matched pairs of patients with type 2 diabetes with SGLT2i and dipeptidyl peptidase-4 inhibitor (DPP4i) treatment for assessing CV outcomes, and 19 951 PS-matched pairs of patients with type 2 diabetes with SGLT2i and DPP4i treatment for assessing kidney outcomes. Patients were followed until December 31, 2018. Statistical analysis was performed from August 2021 to April 2022.
EXPOSURES: Newly stable SGLT2i or DPP4i use in 2017.
MAIN OUTCOMES AND MEASURES: Study outcomes were CV events including hospitalization for heart failure (HHF), 3-point major adverse CV events (3P-MACE: nonfatal myocardial infarction [MI], nonfatal stroke, and CV death), 4-point MACE (4P-MACE: HHF and 3P-MACE), and all-cause death, and chronic kidney disease (CKD). RMST and Cox modeling analyses were applied to estimate treatment effects on study outcomes.
RESULTS: After PS matching, the baseline patient characteristics were comparable between 21 144 patients with stable SGLT2i use (eg, mean [SD] age: 58.3 [10.7] years; 11 990 [56.7%] male) and 21 144 patients with stable DPP4i use (eg, mean [SD] age: 58.1 [11.6] years; 12 163 [57.5%] male) for assessing CV outcomes, and those were also comparable between 19 951 patients with stable SGLT2i use (eg, mean [SD] age: 58.1 [10.7] years; 11 231 [56.2%] male) and 19 951 patients with stable DPP4i use (eg, mean [SD] age: 57.9 [11.5] years; 11 340 [56.8%] male) for assessing kidney outcome. The 2-year difference in RMST between patients with SGLT2i use and patients with DPP4i use was 4.99 (95% CI, 3.56-6.42) days for HHF, 4.12 (95% CI, 2.72-5.52) days for 3P-MACE, 7.72 (95% CI, 5.83-9.61) days for 4P-MACE, 1.26 (95% CI, 0.47-2.04) days for MI, 2.70 (95% CI, 1.57-3.82) days for stroke, 0.69 (95% CI, 0.28-1.11) days for CV death, 6.05 (95% CI, 4.89-7.20) days for all-cause death, and 14.75 (95% CI, 12.99-16.52) days for CKD. Directions of hazard ratios from Cox modeling analyses were consistent with RMST estimates. No association was found between study treatment and the negative control outcome (dental visits for tooth care). Consistent results across sensitivity analyses using high-dimensional PS-matched and PS-weighting approaches supported the validity of primary analysis results. Largest difference in RMST of SGLT2i vs DPP4i use for HHF and CKD was found among patients with established heart failure (30.80 [95% CI, 5.08-56.51] days) and retinopathy (40.43 [95% CI, 31.74-49.13] days), respectively.
CONCLUSIONS AND RELEVANCE: In this comparative effectiveness study, RMST analysis was feasible for translating treatment effects into more clinical intuitive estimates and valuable for quantifying HTEs among diverse patients in routine clinical settings.
参考来源
- Peng ZY, Yang CT, Kuo S, et al. Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan. JAMA Netw Open. 2022. PMID: 36520437. doi:10.1001/jamanetworkopen.2022.46928
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。